Clinical disclaimer: This article is for informational purposes only and does not constitute medical advice. Never start, stop, or change medication without clinical supervision.

Key Points

  • REDEFINE 1: mean body-weight change of -20.4% with CagriSema versus -3.0% with placebo in obesity without diabetes
  • REDEFINE 2: mean body-weight change of -13.7% with CagriSema versus -3.4% with placebo in obesity with type 2 diabetes
  • CagriSema adds amylin biology via cagrilintide — it is not simply more semaglutide
  • Potency alone does not settle the clinical argument — cost, tolerability and long-term maintenance still matter
  • The field may be moving toward mechanism combinations rather than simple dose escalation

The REDEFINE trials mattered because they asked what happens when GLP-1 agonism is combined with amylin agonism in a fixed-dose combination. In REDEFINE 1, mean body-weight change was -20.4% with cagrilintide-semaglutide versus -3.0% with placebo. [1] In REDEFINE 2, in people with type 2 diabetes, mean body-weight change was -13.7% versus -3.4%. [2]

These are not trivial numbers. They suggest that mechanism combination — not just dose escalation — may represent the next phase of serious obesity pharmacotherapy.

What the trials showed

CagriSema is not simply more semaglutide. It brings amylin biology into the conversation via cagrilintide. Amylin affects satiety, food intake and potentially the tolerance of caloric restriction in ways that simple GLP-1 dose escalation cannot reproduce. [1,2]

What most articles miss

Potency alone does not settle the clinical argument. Cost, dose flexibility, adverse effects, comparative effectiveness against tirzepatide and retatrutide, and long-term maintenance strategy all still matter. The better reading is that CagriSema represents a meaningful broadening of mechanism in a field that had become somewhat over-fixated on GLP-1 escalation alone.

Bottom line

The REDEFINE trials matter because they suggest the next gains in obesity medicine may come from mechanism combinations, not merely stronger single-agent branding. That is clinically interesting and commercially consequential. [1,2]

FAQ

What is CagriSema?
CagriSema is a fixed-dose combination of cagrilintide and semaglutide in development for weight management. [1,2]
What did REDEFINE 1 show?
Mean body-weight change of -20.4% with CagriSema versus -3.0% with placebo in obesity without diabetes. [1]
What did REDEFINE 2 show?
Mean body-weight change of -13.7% with CagriSema versus -3.4% with placebo in obesity with type 2 diabetes. [2]
Why is the combination important?
Because it broadens the field beyond simple GLP-1 monotherapy and raises the prospect of mechanism-based combination treatment. [1,2]
Does this prove CagriSema is the best option?
No. Comparative effectiveness, cost, tolerability and longer-term strategy still matter.

References

  1. Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025. nejm.org
  2. Davies MJ, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025. nejm.org